Arcturus Therapeutics Holdings Inc Overview
Industry: Biotechnology
Sector: Healthcare
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mR Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Arcturus Therapeutics Holdings Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $2.1M (-93% YoY). Net loss was -$27M (+92% YoY). R&D expense was $21.5M.
Revenue
$2.1M
-93% YoY
Net loss
-$27M
+92% YoY
R&D expense
$21.5M
reported
G&A expense
$9.5M
reported
What changed
- Revenue -93% YoY to $2.1M.
- Net loss +92% YoY to -$27M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K filing
May 07, 2026
SEC filing
10-Q
May 07, 2026
SEC filing
8-K filing
Mar 03, 2026
SEC filing
10-K
Mar 03, 2026
Earnings release
8-K filing
Mar 03, 2026
SEC filing
10-Q
Nov 12, 2025
SEC filing
8-K filing
Nov 10, 2025
Earnings release
8-K filing
Nov 10, 2025
SEC filing
10-Q
Aug 11, 2025
Earnings release
8-K filing
Aug 11, 2025
SEC filing
8-K filing
Aug 11, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Headline from Yahoo Finance: Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference.
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold (NASDAQ:ARCT)
Headline from Seeking Alpha: Arcturus: Now That It's Come This Low, It's Time To Buy And Hold (NASDAQ:ARCT).
Earnings Per Share
Score 1.00/5
Arcturus Therapeutics Holdings Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.67/5
Arcturus Therapeutics Holdings Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 1.58/5
Arcturus Therapeutics Holdings Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.47/5
Arcturus Therapeutics Holdings Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios